Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey.
Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma, Barcelona, Spain.
J Dermatolog Treat. 2020 Mar;31(2):204-209. doi: 10.1080/09546634.2019.1589639. Epub 2019 Mar 7.
The real-life data on the effectiveness and safety of omalizumab in chronic spontaneous urticaria (CSU) with validated methods are scarce. There is also a lack of information on the use of combination treatments. A retrospective cohort study was done to evaluate the effectiveness and safety of omalizumab in real-life conditions. The patients with CSU treated with omalizumab between 2015 and 2018 were included. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT). A total of 106 patients were included. A complete response (CR) (UAS7:0) and a well-controlled activity (WCA) (UAS7:1 to <6) were observed in 50 (47.2%) and 35 (33%) patients, respectively. The number of patients with an UCT score ≥12 was also significantly increased. Higher rates of CR/WCA were observed with omalizumab monotherapy compared to combination with antihistamines. The combination of dapsone, colchicine, and omalizumab provided additional benefit in a small group. Treatment with omalizumab provided a rapid and sustainable improvement in real-life settings. The use of omalizumab as monotherapy or combined with antihistamines does not show differences in the treatment response. The combination of omalizumab with immunomodulatory agents might be of benefit in selected cases.
在慢性自发性荨麻疹（CSU）中，使用经过验证的方法获得的奥马珠单抗有效性和安全性的真实数据很少。关于联合治疗的使用也缺乏信息。进行了一项回顾性队列研究，以评估奥马珠单抗在真实情况下的有效性和安全性。纳入了 2015 年至 2018 年间接受奥马珠单抗治疗的 CSU 患者。使用 7 天荨麻疹活动评分（UAS7）和荨麻疹控制测试（UCT）评估治疗反应。共纳入 106 例患者。50 例（47.2%）和 35 例（33%）患者分别观察到完全缓解（CR）（UAS7：0）和良好控制的活动（WCA）（UAS7：1 至 <6）。UCT 评分≥12 的患者数量也显著增加。与联合抗组胺药相比，奥马珠单抗单药治疗的 CR/WCA 发生率更高。达普松、秋水仙碱和奥马珠单抗联合使用在一小部分患者中提供了额外的益处。奥马珠单抗治疗在真实环境中提供了快速和可持续的改善。奥马珠单抗作为单药或与抗组胺药联合使用在治疗反应方面没有差异。奥马珠单抗与免疫调节剂联合使用可能对某些病例有益。
